29 unknown, 17 completed, 2 not yet recruiting, 1 recruiting. 33 Phase 2, 7 Phase 1, 7 Phase 3, 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Unknown 20, Completed 10, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 7 | Completed 6, Unknown 1 |
| Phase 3 | 7 | Unknown 5, Completed 2 |
| Phase 4 | 4 | Unknown 4 |
Follow raltitrexed: new trials by email Literature Review of raltitrexed trials Research Report on raltitrexed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC) - Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-12-25 | 2026-01-13 |
| CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody - Colon Cancer, Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 110 | 2024-11-01 | 2024-10-30 |
| CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC Ultrafractionated RT and CGA Guided systemic treatment., data prospectively collected, Ultrafractionated Radiotherapy - Colon Cancer, Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 124 | 2024-11-01 | 2024-10-28 |
| Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer Fruquintinib - Metastatic Colorectal Cancer | Phase 4 | Unknown | The First Affiliated Hospital of Nanchang University | 30 | 2023-10-20 | 2023-11-07 |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1 | Phase 2 | Unknown | Meng Qiu | 66 | 2023-02-20 | 2025-01-22 |
| Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial Oxaliplatin, Doxorubicin, Lobaplatin - Hepatocellular Carcinoma Resectable | Phase 3 | Unknown | Zhujiang Hospital | 90 | 2023-01-01 | 2023-03-13 |
| The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer PD-1 antibody, Capecitabine, 5FU - Recurrent Rectal Cancer | Phase 2 | Unknown | Fudan University | 93 | 2022-11-30 | 2024-10-01 |
| Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial Oxaliplatin, Doxorubicin, Lobaplatin - Liver, Cancer of, Primary Resectable | Phase 3 | Unknown | Zhujiang Hospital | 144 | 2022-09-01 | 2023-03-02 |
| Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy HAIC, Fruquintinib, Tislelizumab - Colorectal Cancer | Phase 2 | Unknown | Fudan University | 39 | 2022-07-12 | 2024-01-17 |
| Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients Regorafenib, Raltitrexed - Regorafenib, Raltitrexed | Phase 1 / Phase 2 | Unknown | China Medical University, China | 50 | 2022-07-01 | 2022-06-29 |
| Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment - Hepatocellular Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 426 | 2022-03-28 | 2022-05-24 |
| SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer Raltitrexed, Irinotecan, Bevacizumab - Advanced Metastatic Colorectal Cancer | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2021-11-12 | 2023-06-08 |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer Fruquintinib and raltitrexed, Fruquintinib - Advanced Colorectal Carcinoma | Phase 2 | Unknown | Fudan University | 136 | 2020-09-28 | 2021-10-26 |
| Raltitrexed in HIPEC Raltitrexed - Colorectal Cancer, Raltitrexed | Phase 1 | Completed | Fudan University | 30 | 2020-09-18 | 2026-02-25 |
| A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer Raltitrexed, Cetuximab - Colorectal Cancer | Phase 2 | Unknown | Jiangsu Cancer Institute & Hospital | 50 | 2019-11-28 | 2021-08-30 |
| The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer raltitrexed for injection, nab-paclitaxel - Pancreatic Cancer, Chemotherapy Effect | Phase 2 | Unknown | Fudan University | 120 | 2019-11-01 | 2020-10-09 |
| Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia rhTPO, irinotecan, Raltitrexed - Recurrent Colorectal Carcinoma, Thrombopenia | Phase 2 | Unknown | Fudan University | 50 | 2019-02-01 | 2019-01-30 |
| RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) Raltitrexed, Capecitabine - Colorectal Cancer | Phase 2 | Unknown | Shenzhen People's Hospital | 100 | 2019-01-28 | 2019-09-09 |
| A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer Radiotherapy Combined With Raltitrexed and Irinotecan - Recurrent Colorectal Cancer | Phase 2 | Unknown | Fudan University | 30 | 2019-01-01 | 2020-08-05 |
| Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus raltitrexed - Esophagus Squamous Cell Carcinoma | Phase 2 | Unknown | Huai'an First People's Hospital | 32 | 2018-09-05 | 2021-04-06 |
Showing 20 of 49. Sign in to see all of them.
Colorectal Neoplasms (14) · Rectal Neoplasms (10) · Colonic Neoplasms (6) · Stomach Neoplasms (3) · Mesothelioma, Malignant (2) · Carcinoma, Hepatocellular (1) · Esophageal Squamous Cell Carcinoma (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Thrombocytopenia (1)
Fudan University (12) · Jiangsu Cancer Institute & Hospital (3) · AstraZeneca (2) · China Medical University, China (2) · Chinese Academy of Medical Sciences (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · National Cancer Institute (NCI) (2) · Zhujiang Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Centre Georges Francois Leclerc (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · Fox Chase Cancer Center (1) · Hebei Tumor Hospital (1) · Huai'an First People's Hospital (1) · Hubei Cancer Hospital (1)
China (31) · United States (4) · France (2) · Italy (2) · Netherlands (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Egypt (1) · Germany (1) · Peru (1) · Poland (1) · Turkey (Türkiye) (1)
Zhen Zhang, MD (2) · Ai Ping Zhou, Doctor of medcine (1) · Alessio G Morganti, Prof (1) · Antonio Avallone, M.D. (1) · Desheng Hu, M.D. (1) · Fuxiang Zhou, M.D. (1) · Gary K. Schwartz, MD (1) · Giuseppe Giaccone, MD, PhD (1) · Jan P. Van Meerbeeck, MD, PhD (1) · Jianhua Wang (1) · Jing Jin, MD (1) · Jinzhang Chen, Study Director (1)
PMID 12047964, PMID 12187070, PMID 12196368, PMID 12565988, PMID 15083176, PMID 15865096, PMID 16192580, PMID 16446322, PMID 18089874, PMID 29946728, PMID 31999946, PMID 32645159, PMID 33567129, PMID 35235653, PMID 36101518, PMID 36212504, PMID 38053659, PMID 38773457, PMID 39223545, PMID 39286935, PMID 40022044, PMID 9006748
2008 (1), P30CA006927 (1), U01CA097452 (1)